Vitarka Therapeutics is a pre-clinical stage biotech focused on developing RNAi therapies using a proprietary non-viral delivery platform. The underlying technology utilizes pore-forming proteins for targeted, cytosolic delivery of RNA therapeutics. Vitarka Therapeutics believes it can unlock new targeted therapeutic approaches for cancer treatment.